Skip to main content

NEUROCRINE BIOSCIENCES INC

For the period ended Apr 9, 2025. Filed Apr 9, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Apr 9, 2025 · Filed Apr 9, 2025

NBIX$164.63+3.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant☒ Filed by a Party other than the Registrant☐

Check the appropriate box:

☐Preliminary Proxy Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive Additional Materials
☐Soliciting Material Pursuant to §240.14a-12

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒No fee required.
☐Fee paid previously with preliminary materials.
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

NEUROCRINE BIOSCIENCES, INC.

6027 Edgewood Bend Court

San Diego, CA 92130

Notice of Annual Meeting of Stockholders

To Be Held on May 21, 2025

TO THE STOCKHOLDERS:

NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting of Stockholders of Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), will be held on May 21, 2025, at 10:30 a.m., local time, at the Company’s corporate offices located at 6027 Edgewood Bend Court, San Diego, California 92130, for the following purposes as more fully described in the Proxy Statement accompanying this Notice:

  1. The election of the four nominees for Class II directors named herein to the Board of Directors to serve for a term of three years;

  2. An advisory vote on the compensation paid to the Company’s named executive officers;

  3. To approve the Company’s 2025 Equity Incentive Plan;

  4. To approve an amendment and restatement of the Company’s 2018 Employee Stock Purchase Plan;

  5. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; and

  6. To transact such other business as may properly come before the Annual Meeting of Stockholders or any continuation, adjournment or postponement thereof.

Only stockholders of record at the close of business on March 24, 2025 are entitled to receive notice of and to vote at the Annual Meeting of Stockholders.

All stockholders are invited to attend the Annual Meeting of Stockholders in person. However, we strongly urge our stockholders not to attend the Annual Meeting in person and to instead submit proxy votes. Our Annual Meeting will be purely functional in format to comply with the relevant legal requirements. There will be no presentations or exhibitions. No refreshments will be provided. Your vote is important. Whether or not you plan to attend the Annual Meeting, we encourage you to submit your proxy or voting instructions as soon as possible to vote your shares. You may vote over the Internet, as well as by telephone or by mailing a proxy or voting instruction form. Please review the instructions on each of your voting options described in these proxy materials. Stockholders attending the Annual Meeting may vote in person even if they have returned a proxy. If you hold shares through an account with a brokerage firm, bank or other nominee, please follow the instructions you receive from such firm, bank or other nominee to vote your shares.

By Order of the Board of Directors,

Darin Lippoldt

Chief Legal Officer and Corporate Secretary

San Diego, California

April 9, 2025

Important Notice Regarding the Availability of Proxy Materials for the Stockholders’

Meeting to be Held on May 21, 2025 at 10:30 a.m. Local Time at

6027 Edgewood Bend Court, San Diego, California 92130.

The Proxy Statement and Annual Report to stockholders are available at

www.proxyvote.com. Please have the control number on your proxy card available.

A copy of the Company’s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2024 is available without charge upon written request to the Company’s Corporate Secretary at

6027 Edgewood Bend Court, San Diego, California 92130.

TABLE OF CONTENTS

Proxy Summary1Compensation Philosophy and Objectives49
About the Annual Meeting2Overall Compensation Determination Process50
Security Ownership of Certain Beneficial Owners and Management5Components of Executive Compensation53
Our Board of Directors72024 Named Executive Officer Compensation Decisions55
General7Other Features of our Executive Compensation Program59
Director Biographies of Class II Directors Nominated for Reelection at the 2025 Annual Meeting of Stockholders7Officer Equity Ownership Guidelines60
Director Biographies of Class I and Class III Directors not Nominated for Reelection at the 2025 Annual Meeting of Stockholders8Equity Trading Policies and Procedures60
The Board of Directors and Corporate Governance Matters11Equity Grant Practices61
General11Compensation Recoupment Policy61
Corporate Governance Best Practices11Tax and Accounting Considerations61
Board of Directors Overview12Risk Analysis of Our Compensation Program62
Board Leadership Structure12Executive Compensation and Other Information63
Board Independence13Summary Compensation Table63
Classified Board Structure13Grants of Plan-Based Awards During 202464
Overboarding Policy13Agreements with Named Executive Officers Effective During Fiscal Year 202465
Director Refreshment13Executive Severance Plan66
Board and Committee Meetings During 202414Amendment and Restatement of Employment Arrangements67
Information About Board Committees14Outstanding Equity Awards at Fiscal Year-End68
Compensation Committee Interlocks and Insider Participation15Option Exercises and Stock Vested During the Year69
Director Nomination Process15Potential Payments upon Termination or Change-in-Control70
Board Self-Assessment15CEO Pay Ratio74
Board Education16Item 402(v) Pay Versus Performance75
Identification and Evaluation of Nominees for Director16Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information78
Proxy Access16Directors Compensation Summary79
Process for Stockholder Communications with the Board of Directors16Non-Employee Director Compensation Philosophy79
Role of Board in Risk Oversight17Non-Employee Director Compensation for 202480
Corporate Responsibility17Director Compensation Table80
Risk Assessment Concerning Compensation Practices and Policies17Non-Employee Director Compensation for 202581
Role of Board in Succession Planning17Non-Employee Director Equity Ownership Guidelines81
Policy Regarding Board Member Attendance at the Company's Annual Meeting17Additional Information81
Report of the Audit Committee18Related Person Transactions81
Principal Accountant Fees and Services19Other Matters81
Compensation Committee Report20Additional Information81
Proposal One: Election of Directors21Special Note Regarding Forward-Looking Statements82
Proposal Two: Advisory Vote on Compensation Paid to the Company's Named Executive Officers23Appendix A - 2025 Equity Incentive Plan
Proposal Three: Approval of the Company's 2025 Equity Incentive Plan24Appendix B - 2018 Employee Stock Purchase Plan
Proposal Four: Approval of an Amendment and Restatement of the 2018 Employee Stock Purchase Plan36
Equity Compensation Plans41
Proposal Five: Ratification of Appointment of Independent Registered Public Accounting Firm42
Executive Officers43
Compensation Discussion and Analysis45
Executive Summary45
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.